Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001104659-20-140308
Filing Date
2020-12-29
Accepted
2020-12-29 21:52:38
Documents
1
Period of Report
2020-12-22

Document Format Files

Seq Description Document Type Size
1 FORM 4 tm2039455d2_form4.html 4  
1 FORM 4 tm2039455d2_form4.xml 4 4014
  Complete submission text file 0001104659-20-140308.txt   5394
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Issuer) CIK: 0001750149 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address
Werner Milton H. (Reporting) CIK: 0001827621 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39676 | Film No.: 201423917